ENZYCHEM LIFESCIENCES
Enzychem Lifesciences is a Global New Drug Development Company that was founded on the most advanced life sciences and technologies of medicinal chemistry in July 1999. With its Global New Drug R&D center located in KAIST in Daejeon and its two GMP manufacturing plants in Seoul, it has since been developing and producing APIs and functional health foods, and developing global new drugs as the leader of the field.
ENZYCHEM LIFESCIENCES
Industry:
Biotechnology Life Science
Address:
Seoul, Seoul-t'ukpyolsi, South Korea
Country:
South Korea
Website Url:
http://www.enzychem.com
Total Employee:
51+
Status:
Active
Contact:
+82 2-6213-7131
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Font Awesome Wordpress Plugins
Similar Organizations
Amwise Diagnostic
Amwise Diagnostic is a leader in precision medicine technology for cancer.
BioAdvance
BioAdvance is a Pennsylvania-based venture capital firm that provides funding to life sciences startups.
Current Employees Featured
Stock Details
Official Site Inspections
http://www.enzychem.com
- Host name: 67.156.208.35.bc.googleusercontent.com
- IP address: 35.208.156.67
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Enzychem Lifesciences"
About us โ Global New Drug Development Company
Enzychem Lifesciences USA, Inc Established and Global Operation Launched . MARCH. Fast Track Designation by US FDA on CRIOM. FEBRUARY. Listed on the KOSDAQ Stock Market โฆSee details»
Global New Drug Development Company | โ Enzychem โฆ
Mar 9, 2022 ENGLEWOOD CLIFFS, N.J.โ(BUSINESS WIRE)โEnzychem Lifesciences (KOSDAQ: 183490), a late-stage biotechnology company, announced today that the company has completed t Explore further. United โฆSee details»
Enzychem Lifesciences - Crunchbase Company Profile โฆ
Enzychem Lifesciences is a Global New Drug Development Company that was founded on the most advanced life sciences and technologies of medicinal โฆSee details»
์์ง์ผ์๋ช ๊ณผํ
์์ธ์ฌ๋ฌด์ : ์์ธ์ ์์ด๊ตฌ ๊ฐ๋จ๋๋ก 27 at์ผํฐ 14์ธต, 10์ธต tel. 02-501-1084 fax. 02-501-1201 ์์ฝํ์ฐ๊ตฌ์/๊ณต์ฅ : ์ถฉ๋ถ ์ ์ฒ์ ๋ฐ์ด์ค๋ฐธ๋ฆฌ๋ก 59 (์์๋) tel. 043-652-2845 fax. 043-652-2847 โฆSee details»
Enzychem Lifesciences - LinkedIn
Enzychem Lifesciences, Corp. (KOSDAQ:183490) is a global biopharmaceutical company headquartered in Seoul, Korea, which is dedicated to developing new drugs and APIs (Active โฆSee details»
Enzychem Lifesciences
Feb 25, 2025 Enzychem Lifesciences Co., Ltd. is a South Korean biopharmaceutical company focused on drug discovery and the development of novel treatments for cancer and โฆSee details»
Enzychem Lifesciences Company Description - Stock Analysis
Mar 14, 2025 Enzychem Lifesciences Corporation engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory โฆSee details»
ENZYCHEM LIFESCIENCES Corp. - Drug pipelines, Patents, Clinical โฆ
Explore ENZYCHEM LIFESCIENCES Corp. with its drug pipeline, therapeutic area, technology platform, 7 clinical trials, 13 news, and 1 literature, Disease Domain ...See details»
Enzychem Lifesciences Corporation - PharmaSource
Enzychem Lifesciences Corporation is a Global New Drug Development Company that was founded on the most advanced life sciences and technologies of medicinal chemistry in July โฆSee details»
Organization | Enzychem Lifesciences
Organization Overview. First Clinical Trial. 2015 NCT02532712. First Marketed Drug. None First NDA Approval. None Last Known Activity ... Enzychem Lifesciences Corporation Active โฆSee details»
J. Sam Lee - Chief Scientific Officer - Enzychem Lifesciences
Enzychem Lifesciences · CAR-Macrophage cancer therapy, Dendritic cell (DC) therapy, Immune cell and stem cell derived exosomes, Induced Pluripotent Stem Cells (iPSCs). · Experience: โฆSee details»
์์ง์ผ์๋ช ๊ณผํ - enzychem.co.kr
์์ธ์ฌ๋ฌด์ : ์์ธ์ ์์ด๊ตฌ ๊ฐ๋จ๋๋ก 27 at์ผํฐ 14์ธต, 10์ธต tel. 02-501-1084 fax. 02-501-1201 ์์ฝํ์ฐ๊ตฌ์/๊ณต์ฅ : ์ถฉ๋ถ ์ ์ฒ์ ๋ฐ์ด์ค๋ฐธ๋ฆฌ๋ก 59 (์์๋) tel. 043-652-2845 fax. 043-652-2847 โฆSee details»
Enzychem Lifesciences - Tech Stack, Apps, Patents & Trademarks
Organization. Enzychem Lifesciences . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech Count 12. ...See details»
ARS โ Global New Drug Development Company - enzychem.com
Acute Radiation Syndrome (ARS) (sometimes known as radiation toxicity or radiation sickness) is an acute illness caused by irradiation of the entire body (or most of the body) by a high dose of โฆSee details»
KQ:183490 Financials | Enzychem Lifesciences Corp - Investing.com
Enzychem Lifesciences Corp (183490) KOSDAQ. Currency in KRW. Add to Watchlist. 1,259 +9 (+0.72 %) Closed 02:29:59. Fair Value. An estimate of a stock's true price based on valuation โฆSee details»
Enzychem Lifesciences Corp (183490) - Investing.com Canada
Feb 17, 2025 Discover who owns Enzychem Lifesciences, including major 183490 shareholders and institutional investors.See details»
Mosedipimod by Enzychem Lifesciences for Coronavirus Disease โฆ
Dec 30, 2024 Mosedipimod is under clinical development by Enzychem Lifesciences and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory โฆSee details»
Who Owns Enzychem Lifesciences? 183490 Shareholders
Feb 17, 2025 Discover who owns Enzychem Lifesciences, including major 183490 shareholders and institutional investors.See details»
Mosedipimod - Enzychem Lifesciences - AdisInsight - Springer
08 Jul 2024 Enzychem Lifesciences plans a phase II trial for Atopic dermatitis (PO, capsules) in May 2025 (NCT06487000) ... If your organization or you do not have a subscription, try one of โฆSee details»
Enzychem Lifesciences Q&A: How are career development
How are career development opportunities at Enzychem Lifesciences? ... For Employers. Post a JobSee details»